Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What would u have them say? There is no new news to present. They can't timeline the FDA approval. They can't talk about potential candidates. They simply outlined what has been accomplished this year. Which has been a tremendous amount. To new people to the company, I'm sure the synopsis is quite informative. Give the guys a break!!.
Nicely said. Thank you.
Stumps the hemostatic market at present is over 3 billion dominated by Baxter and Ethicon. I would think a company like Becton Dickinson would be very interested in taking a third of that market with a product that is ready to go. It takes time to develop a competitive FDA approved product that is superior to what is already on the market. I think the SES board needs you. We are just fine here.
It would be interesting to know how many shareholders there are holding this security. I would gather it is relatively small compared to the float size. Thus, many shares are just not available to be traded. Everyone holds their shares.
Trading has been done in very uniform lots today and yesterday as to not move the price. An interesting strategy. You can tell the quantity units are part of a larger package (buy or sell) by the timing.
I don't believe they will have to do a separate FDA study for the colloid gel. It is the same product just in a different form. Like a pill vs. a gel capsule. Same product. It should be rolled up into the original FDA application. They are demonstrating that it works the same way by safety and efficacy.
HENDERSON, Nev., Oct. 17, 2019 (GLOBE NEWSWIRE) -- United Health Products, Inc. (UEEC), (“UHP” or the “Company”), developer, manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose gauze, today announced that it will relocate the majority of its manufacturing operations to a United States facility. UHP is recently partnering with an established contract manufacturing company and is leasing “clean room” space at the partner’s state-of-the-art facility in the Baltimore suburb of Westminster, Maryland. The facility is ISO 9001 and 13485 certified, and offers certain engineering and technical services that will help UHP rapidly increase production of existing and new HemoStyp formats, in anticipation of a successful FDA Class III PMA application approval, the potential acquisition of the Company or a strategic partnership. Once fully operational, the facility will be capable of manufacturing up to 20 million square inches of HemoStyp gauze monthly. Additional formulations of the HemoStyp product designed for the specialized human surgical market will also be produced at this facility. UHP is onshoring its production operations to improve its order response time, reduce freight costs and improve scalability.
UHP has been working to relocate manufacturing to the United States since the beginning of the year. The Company has enjoyed a successful relationship with its Chinese associates who are providing support and technical assistance to UHP’s effort to commission its U.S. manufacturing operation. They will continue to supply the raw material for HemoStyp and produce certain finished, adhesive based products for non-surgical markets. The Company’s Chinese associates will continue to be an intricate part of the company’s retail product process and provide UHP with continuous manufacturing expertise.
About United Health Products
United Health Products develops technology; manufactures and markets patented hemostatic products for the healthcare and wound care sectors. The product, HemoStyp, is derived from oxidized regenerated cellulose. HemoStyp is an all-natural product designed to control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
Company Contact:
United Health Products, Inc.
877-358-3444
IR Contact :
PAN Consultants Ltd.
Philippe Niemetz 212-344-6464 p.niemetz@panconsultants.com
Source: United Health Products Inc. 2019 GlobeNewswire, Inc.
Perhaps Doug has set up an veterinary exclusive partnership with Covetrus. Patterson would be cut out. Just something to ruminate on.
He's been very busy on the SES board. Lol.
Super clown thanks for making me laugh with your response.
If it makes that big of difference, I'll start using you're.
To each his own. Laughing all the way to the bank.
How many years was Brent Sanders paid millions of dollars each year for being the CEO of Allergan? He just didn't get his all at one time!!.
No one yells at anyone on this board ( except Trust). If your going to post only negative stuff in your post, yet claim your neutral, your not being representative of both sides. People will become defensive. Example: The CEO getting a huge bonus. Let's do some math. (10.00-1.40)÷1.40 = 6.14 or 614 % return with today's price and just assuming a 10 dollar sale price. Who would criticize that? But yet it was. You can be sure your going to get a counter response.
I think you're right you should remain sitting on the fence on this one.
A private equity firm or for that matter a public listed company doesn't gave a hoot about whether UEEC is public or private. If they want the product, the company will be bought. No reason to list any where.
That would make my Holidays. I think January is more likely. IMO.
Good luck on that one. PS, sometimes it's good not to announce your intentions.
MM's this morning.
You're not the only one who will be buying more. Lol
Try Elon Musk. Lol
Like I said earlier they are in no position to talk. The information has been submitted. The FDA will post when appropriate. They can't talk about negotiations. U basically believe in the product or not. Yes, I do believe the CC could have been handled better but in the end, does it matter? Big picture.
Simply put. They are not in a position to talk about private negotiations taking place.
Bloodstop does not have class 3 approval from the FDA. It is used for surface wounds. Hope this helps answer your question. HemoStryp will be a class 3 FDA approved product once approved. Meaning it can be used in surgical internal settings.
FDA approved for external use, BloodSTOP can also be used to stop bleeding from deep lacerations.
I suspect within 3 months everyone's dreams or disappointments will be met. The company really has done a fantastic job of bringing a product to the FDA's doorstep with very limited resources and a great deal of animosity toward Mr. Beplate succeeding. I would suspect some jealously on their part. No matter the amount of pumping or short mongering is going to change the outcome. The final act has been set in motion. The FDA is an independent body.
You state the stock is garbage How about the product? 1st class hemostatic gauze product that will be marketed to compete with surgicel. Lol.to the bank.
What i really would like to see is a reverse split say 30 for 1. Shakes out marginal players.
I don't see that occurring. The company is in compliance with their SEC filings. Of course, one would know that if they would do their DD.
Obviously, someone(people) has/have a grudge against Mr. Beplate. Unfortunately, they r trying their best to hurt UEEC and in the process hurting the shareholders who actually believe in the company. I do believe in the end the product that proved superiority to surgicel will get FDA approval and brought to market. It's just a shame innocent people are being manipulated for someone's selfish behavior.
Chop you can do better than that post. The product will now be entering a new market. Operative.
A market that couldn't be marketed to without FDA approval. FDA approval which should be coming soon with fast track status. Second new configurations are being developed to use. Read the company communications. Third the product will be produced in the USA. Fourth, as stated in the company's communications there has never been the intention of selling the product on there own but to partner or sell outright to another large established player once the suite of configurations are completed. Fifth it has been proven to the FDA by trial results that surgicel is an inferior product to the United Health product.
Your rebuttal came in the form of a defamation lawsuit against WD. Personally, I think you like to interact on these boards to get attention.
Quite a battle between a short attack this morning and positive news!. Who will win out today?
Rodman, please stop posting that post. You do nobody a favor except yourself. People do their own DD and have certainly read all the news posts and boards. Just sit back and let this unfold. It will be a memory in a few months with FDA approval. Just control your emotions and buy more. This us a God send opportunity to get in at this price.
Somebody sure wants this down. Moving manufacturing to the USA.
There maybe already a bidding war. UEEC sets the rules.
The UEEC study was top notch and a preapproval offer contingent would minimize the buyers risk while scooping up a product before a rival could acquire it.
The question maybe to consider is whether a buyer will make a binding offer pre FDA approval contingent upon final approval?
I agree with you that it would be nice to hear some news but in reality, it takes time. Give it another month. On the slow drift pick up a few shares.